Back

Medicus Pharma confirms 200-microgram SkinJect dose for Gorlin syndrome studies

Verifying
  • Medicus Pharma confirmed SkinJect’s 200-microgram dose for further Gorlin syndrome studies.
  • The confirmed dose is 200 micrograms for the SkinJect patch.
  • FDA approval for a pivotal trial is underway, alongside an out-licence exploration.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.